£30M clinical study will enhance the understanding of NASH cirrhosis

The most extensive clinical study into liver cirrhosis ever conducted worldwide has been announced by Newcastle University, University of Edinburgh and leading research-driven global biopharmaceutical company, Boehringer Ingelheim.

Fecal microbiota transplantation boosts survival in metastatic colorectal cancer treatment

A recent study in eClinicalMedicine found that fecal microbiota transplantation, combined with fruquintinib and tislelizumab, significantly improved survival rates in patients with microsatellite stable metastatic

November 16, 2023

For PCI, Intravascular Ultrasound Guidance Bests Angiography Guidance

ATLANTA — The use of intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) in patients with acute coronary syndromes resulted in better outcomes compared with angiography-guided

April 10, 2024

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update – Biotech Investments

Issuer: Immunic, Inc. / Key word(s): Annual Results 22.02.2024 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic, Inc.

February 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.